Inactive Instrument

BioSpecifics Technologies Corp.

BSTC

US0909311062

Biotechnology & Medical Research

BioSpecifics Technologies Corp. Provides Revenue Guidance for the Second Half of 2020

August 10, 2020 at 05:33 pm IST

BioSpecifics Technologies Corp. provided revenue guidance for the second half of 2020. For the second half, the company is projecting a rebound in XIAFLEX royalties in the second half of 2020.

Latest news about BioSpecifics Technologies Corp.

Fourth Amended Joint Reorganization Plan Approved for Endo International plc	22/03	CI
Fourth Amended Joint Reorganization Plan Filed by Endo International plc	18/03	CI
Third Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	20/02	CI
Motion for Exclusivity Period Extension Approved For Endo International plc	25/01	CI
Combined Hearing for Disclosure Statement and Plan Approved for Endo International plc	12/01	CI
Second Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	09/01	CI
First Amended Reorganization Plan and Disclosure Statement Filed by Endo International plc	05/01	CI
Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	19/12	CI
Third Motion for Exclusivity Period Extension Approved For Endo International plc	16/11	CI
Second Motion for Exclusivity Period Extension Approved For Endo International plc	31/23/31	CI
Two Affiliate Companies Joined Endo International plc Bankruptcy	25/23/25	CI
First Motion for Exclusivity Period Extension Approved For Endo International plc	03/23/03	CI
First Motion for Exclusivity Period Extension Filed by Endo International plc	14/22/14	CI
Motion for Asset Sale Filed by Endo International plc	23/22/23	CI
Motion for Asset Sale Approved for Endo International plc	27/22/27	CI
Motion for Asset Sale Filed by Endo International plc	22/22/22	CI
Motion for De Minimis Assets Sale Filed by Endo International plc	02/22/02	CI
Motion for Joint Administration Approved for Endo International plc	17/22/17	CI
Motion for Joint Administration Filed by Endo International plc	16/22/16	CI
Endo International plc Filed for Bankruptcy	16/22/16	CI
BioSpecifics Technologies Corp. Announces Management Changes	02/20/02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from S&P Global BMI Index	02/20/02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from S&P TMI Index	02/20/02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from Russell 2500 Index	02/20/02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from Russell Small Cap Comp Growth Index	02/20/02	CI

Chart BioSpecifics Technologies Corp.

Duration

Period

More charts

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.38%	11TCr
BIONTECH SE	-12.64%	2.22TCr
ARGENX SE	+0.44%	2.13TCr
GENMAB A/S	-4.18%	1.9TCr
WUXI APPTEC CO., LTD.	-37.85%	1.85TCr
BEIGENE, LTD.	-8.58%	1.68TCr
SAREPTA THERAPEUTICS, INC.	+37.41%	1.25TCr
LEGEND BIOTECH CORPORATION	-23.95%	808.97Cr

Bio Therapeutic Drugs